BACKGROUND AND OBJECTIVES: Poor growth is a consequence of CKD, but can often be partially or fully prevented or corrected with the use of a number of medications. The extent of nonadherence with medications used to treat or mitigate growth failure in CKD has not been examined prospectively in children with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The prevalence of both prescription of and nonadherence to recombinant human growth hormone (rhGH), phosphate binders, alkali, active vitamin D, nutritional vitamin D, iron, and erythrocyte-stimulating agents was summarized over the first seven visits of the Chronic Kidney Disease in Children cohort study. The association between self-reported nonadherence to each medication group and the mean annual change in age- and sex-specific height z score was quantified using seven separate linear regression models with generalized estimating equations. RESULTS: Of 834 participants, 597 reported use of at least one of these medication groups and had adherence data available. Nonadherence ranged from 4% over all visits for erythrocyte-stimulating agents to 22% over all visits for nutritional vitamin D. Of the study participants, 451 contributed data to at least one of the analyses of adherence and changes in height z score. Children nonadherent to rhGH had no change in height z score, whereas those adherent to rhGH had a significant improvement of 0.16 SDs (95% confidence interval, 0.05 to 0.27); the effect size was slightly larger and remained significant after adjustment. Among participants with height≤3rd percentile and after adjustment, adherence to rhGH was associated with a 0.33 SD (95% confidence interval, 0.10 to 0.56) greater change in height z score. Nonadherence with other medication groups was not significantly associated with a change in height z score. CONCLUSIONS: Self-reported nonadherence to rhGH was associated with poorer growth velocity in children with CKD, suggesting an opportunity for intervention and improved patient outcome.
BACKGROUND AND OBJECTIVES: Poor growth is a consequence of CKD, but can often be partially or fully prevented or corrected with the use of a number of medications. The extent of nonadherence with medications used to treat or mitigate growth failure in CKD has not been examined prospectively in children with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The prevalence of both prescription of and nonadherence to recombinant humangrowth hormone (rhGH), phosphate binders, alkali, active vitamin D, nutritional vitamin D, iron, and erythrocyte-stimulating agents was summarized over the first seven visits of the Chronic Kidney Disease in Children cohort study. The association between self-reported nonadherence to each medication group and the mean annual change in age- and sex-specific height z score was quantified using seven separate linear regression models with generalized estimating equations. RESULTS: Of 834 participants, 597 reported use of at least one of these medication groups and had adherence data available. Nonadherence ranged from 4% over all visits for erythrocyte-stimulating agents to 22% over all visits for nutritional vitamin D. Of the study participants, 451 contributed data to at least one of the analyses of adherence and changes in height z score. Children nonadherent to rhGH had no change in height z score, whereas those adherent to rhGH had a significant improvement of 0.16 SDs (95% confidence interval, 0.05 to 0.27); the effect size was slightly larger and remained significant after adjustment. Among participants with height≤3rd percentile and after adjustment, adherence to rhGH was associated with a 0.33 SD (95% confidence interval, 0.10 to 0.56) greater change in height z score. Nonadherence with other medication groups was not significantly associated with a change in height z score. CONCLUSIONS: Self-reported nonadherence to rhGH was associated with poorer growth velocity in children with CKD, suggesting an opportunity for intervention and improved patient outcome.
Authors: Amira Al-Uzri; Matthew Matheson; Debbie S Gipson; Susan R Mendley; Stephen R Hooper; Ora Yadin; David J Rozansky; Marva Moxey-Mims; Susan L Furth; Bradley A Warady; Arlene C Gerson Journal: J Pediatr Date: 2013-04-26 Impact factor: 4.406
Authors: Norkasihan Ibrahim; Ian Ck Wong; Susan Patey; Stephen Tomlin; Manish D Sinha; Yogini Jani Journal: Pediatr Nephrol Date: 2012-03-28 Impact factor: 3.714
Authors: C S Wong; D S Gipson; D L Gillen; S Emerson; T Koepsell; D J Sherrard; S L Watkins; C Stehman-Breen Journal: Am J Kidney Dis Date: 2000-10 Impact factor: 8.860
Authors: Robert J Kuczmarski; Cynthia L Ogden; Shumei S Guo; Laurence M Grummer-Strawn; Katherine M Flegal; Zuguo Mei; Rong Wei; Lester R Curtin; Alex F Roche; Clifford L Johnson Journal: Vital Health Stat 11 Date: 2002-05
Authors: Nancy M Rodig; Kelly C McDermott; Michael F Schneider; Hilary M Hotchkiss; Ora Yadin; Mouin G Seikaly; Susan L Furth; Bradley A Warady Journal: Pediatr Nephrol Date: 2014-04-12 Impact factor: 3.714
Authors: Tom D Blydt-Hansen; Christopher B Pierce; Yi Cai; Dmitri Samsonov; Susan Massengill; Marva Moxey-Mims; Bradley A Warady; Susan L Furth Journal: Clin J Am Soc Nephrol Date: 2013-11-21 Impact factor: 8.237
Authors: Guillermo Hidalgo; Derek K Ng; Marva Moxey-Mims; Maria Lourdes Minnick; Tom Blydt-Hansen; Bradley A Warady; Susan L Furth Journal: Am J Kidney Dis Date: 2013-08-07 Impact factor: 8.860
Authors: Elaine Ku; Joel D Kopple; Charles E McCulloch; Bradley A Warady; Susan L Furth; Robert H Mak; Barbara A Grimes; Mark Mitsnefes Journal: Am J Kidney Dis Date: 2017-11-11 Impact factor: 8.860
Authors: Edwin Patino; Stephen B Doty; Divya Bhatia; Kelly Meza; Yuan-Shan Zhu; Stefano Rivella; Mary E Choi; Oleh Akchurin Journal: Kidney Int Date: 2020-06-20 Impact factor: 10.612
Authors: Oleh Akchurin; Angara Sureshbabu; Steve B Doty; Yuan-Shan Zhu; Edwin Patino; Susanna Cunningham-Rundles; Mary E Choi; Adele Boskey; Stefano Rivella Journal: Am J Physiol Renal Physiol Date: 2016-07-20
Authors: Derek K Ng; Megan K Carroll; Frederick J Kaskel; Susan L Furth; Bradley A Warady; Larry A Greenbaum Journal: Pediatr Nephrol Date: 2021-06-11 Impact factor: 3.651